ArticleFrontiers in pharmacology2025
Impact of different treatment strategies on therapeutic efficacy and biomarkers in children with IVIG-resistant Kawasaki disease: a retrospective cohort study.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Triple-vessel coronary involvement and giant aneurysm in a 6-year-old boy with kawasaki disease: a case report.BMC cardiovascular disorders · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Intravenous immunoglobulin (IVIG) is the standard first-line treatment for Kawasaki disease (KD), although 10%-20% of patients are resistant to initial IVIG therapy. This study investigates retreatment strategies and associated biomarkers in IVIG-resistant KD patients. Methods: This retrospective analysis included 68 IVIG-resistant KD patients from the Children's Hospital Affiliated to Shandong University. Patients were categorized into three retreatment groups: glucocorticoids (GC) (Group A), IVIG retreatment (Group B), and combination therapy (Group C). Clinical characteristics, laboratory parameters, and therapeutic outcomes were compared, with multivariate logistic regression identifying biomarker correlations. Results: Despite significant differences in pre-treatment levels of C-reactive protein (CRP) and alanine aminotransferase (ALT) across groups, the combined overall response rate for all three groups following different retreatment strategies exceeded 98%. Multivariate logistic regression analysis identified pretreatment eosinophil percentage (EOS%) and albumin (ALB) levels as independent predictors of favorable outcomes, while elevated CRP was significantly associated with adverse outcomes. Furthermore, an increase in EOS% was observed after IVIG retreatment, suggesting a possible modulation of T helper 2 (Th2) immune responses by this intervention. Changes in coronary artery dilation further supported the potential benefits of GC monotherapy and combination therapy in mitigating acute vascular injury. Conclusion: Both GC and IVIG, either alone or in combination, are effective treatments for IVIG-resistant KD. EOS%, CRP, and ALB may serve as independent prognostic markers in children with IVIG-resistant KD, providing a foundation for personalized retreatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.